Table 1.
Clinical Characteristics of Study Population at the Baselinea
| CTR | FEP | CHR | |
|---|---|---|---|
| N (total) | 48 | 44 | 22 |
| N (Turku, Finland) | 31 | 30 | 22 |
| N (London, UK) | 17 | 14 | N/A |
| Sex (male, female) | 31, 17 | 26, 18 | 11, 11 |
| BMI (± SD) | 24.5 (3.8) | 24.3 (4.2) | 25.5 (5.7) |
| Age (± SD) (n) | 27.5 (5.9) (48) | 26.9 (6.3) (42) | 26.2 (5.0) (9) |
| GAF score (± SD) (n) | 92.0 (3.8) (36) | 46.6 (16.0) (39) | 53.0 (1) (10) |
| PANSS TOT (± SD) (n) | 30.4 (0.9) (30) | 70.9 (24.6) (40) | 55.8 (15.1) (10) |
| Antipsychotic CPZE (± SD) | |||
| Turku, Finland (n = 23 FEP, n = 9 CHR) | N/A | 221.8 (± 115.0) | 207.91(± 102.2) |
| London, UK (n = 2 FEP) | N/A | 60 (N/A) | N/A |
Note: CTR, healthy controls; FEP, first-episode psychosis group; CHR, clinical high-risk for psychosis group; SD, standard deviation; CPZE, chlorpromazine equivalence.
aStudy populations are from Turku, Finland and London, UK.